Indirab Vaccine is a highly purified rabies vaccine formulated for human use, containing 2.5 IU of inactivated rabies virus antigen per dose. It is indicated for active immunization against rabies virus infection in individuals at risk of exposure through animal bites or scratches, as well as for post-exposure prophylaxis following potential rabies exposure. The vaccine stimulates the production of virus-neutralizing antibodies, providing protective immunity and reducing the risk of developing rabies, a fatal viral encephalitis. Indirab Vaccine is administered intramuscularly according to established immunization schedules, typically involving multiple doses to ensure adequate immune response. It is suitable for use in both pre-exposure prophylaxis for high-risk populations such as veterinarians, animal handlers, and travelers to endemic areas, and post-exposure treatment in conjunction with wound management and rabies immunoglobulin when indicated. The vaccine is contraindicated in individuals with known hypersensitivity to any component of the formulation. Common adverse reactions may include mild local injection site reactions such as pain, redness, or swelling, and systemic effects like fever or headache. Indirab Vaccine should be stored and handled according to manufacturer guidelines to maintain potency and efficacy. Healthcare professionals should assess patient history and exposure risk before administration.